Hendrik Bartolomaeus

Dr. Hendrik Bartolomaeus

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2017 in Nature
Verified
Journal Article
Closed access
PDF file
NWNicola Wilck
Nicola Wilck
MMMariana G. Matus
Mariana G. Matus
SKSean M. Kearney
Sean M. Kearney
SOScott Olesen
Scott Olesen
KFKristoffer Forslund
Kristoffer Forslund
DMDominik Muller
Dominik Muller

12 March 2019 in Circulation
Verified
Journal Article
Open access
HBHendrik Bartolomaeus
Hendrik Bartolomaeus
ABAndrás Balogh
András Balogh
MYMina Yakoub
Mina Yakoub
SHSusanne Homann
Susanne Homann
LMLajos Markó
Lajos Markó
NWNicola Wilck
Nicola Wilck
Background: Arterial hypertension and its organ sequelae show characteristics of T cell–mediated inflammatory diseases. Experimental anti-inflammatory therapies have been shown to ameliorate hypertensive end-organ damage. Recently, the CANTOS study (Canakinumab Antiinflammatory Thrombosis Outcome Study) targeting interleukin-1β demonstrated that anti-inflammatory therapy reduces cardiovascular risk. The gut microbiome plays a pivotal role in immune homeostasis and cardiovascular health. Short-chain fatty acids (SCFAs) are produced from dietary fiber by gut bacteria and affect host immune homeostasis. Here, we investigated effects of the SCFA propionate in 2 different mouse models of hypertensive cardiovascular damage. Methods: To investigate the effect of SCFAs on hypertensive cardiac damage and atherosclerosis, wild-type NMRI or apolipoprotein E knockout–deficient mice received propionate (200 mmol/L) or control in the drinking water. To induce hypertension, wild-type NMRI mice were infused with angiotensin II (1.44 mg·kg –1 ·d –1 subcutaneous) for 14 days. To accelerate the development of atherosclerosis, apolipoprotein E knockout mice were infused with angiotensin II (0.72 mg·kg –1 ·d –1 subcutaneous) for 28 days. Cardiac damage and atherosclerosis were assessed using histology, echocardiography, in vivo electrophysiology, immunofluorescence, and flow cytometry. Blood pressure was measured by radiotelemetry. Regulatory T cell depletion using PC61 antibody was used to examine the mode of action of propionate. Results: Propionate significantly attenuated cardiac hypertrophy, fibrosis, vascular dysfunction, and hypertension in both models. Susceptibility to cardiac ventricular arrhythmias was significantly reduced in propionate-treated angiotensin II–infused wild-type NMRI mice. Aortic atherosclerotic lesion area was significantly decreased in propionate-treated apolipoprotein E knockout–deficient mice. Systemic inflammation was mitigated by propionate treatment, quantified as a reduction in splenic effector memory T cell frequencies and splenic T helper 17 cells in both models, and a decrease in local cardiac immune cell infiltration in wild-type NMRI mice. Cardioprotective effects of propionate were abrogated in regulatory T cell–depleted angiotensin II–infused mice, suggesting the effect is regulatory T cell–dependent. Conclusions: Our data emphasize an immune-modulatory role of SCFAs and their importance for cardiovascular health. The data suggest that lifestyle modifications leading to augmented SCFA production could be a beneficial nonpharmacological preventive strategy for patients with hypertensive cardiovascular disease.

16 October 2020 in Science Advances
Verified
Journal Article
Open access
IKInna Kviatkovsky
Inna Kviatkovsky
HCHelen M. Chrzanowski
Helen M. Chrzanowski
EAEllen G. Avery
Ellen G. Avery
HBHendrik Bartolomaeus
Hendrik Bartolomaeus
SRSven Ramelow
Sven Ramelow
Quantum light enables mid-IR microscopy with fast acquisition and ultralow intensities using a standard CMOS camera.

30 March 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
AMAndrás Maifeld
András Maifeld
HBHendrik Bartolomaeus
Hendrik Bartolomaeus
ULUlrike Löber
Ulrike Löber
EAEllen G. Avery
Ellen G. Avery
NSNico Steckhan
Nico Steckhan
SFSofia Kirke Forslund
Sofia Kirke Forslund
Periods of fasting and refeeding may reduce cardiometabolic risk elevated by Western diet. Here we show in the substudy of NCT02099968, investigating the clinical parameters, the immunome and gut microbiome exploratory endpoints, that in hypertensive metabolic syndrome patients, a 5-day fast followed by a modified Dietary Approach to Stop Hypertension diet reduces systolic blood pressure, need for antihypertensive medications, body-mass index at three months post intervention compared to a modified Dietary Approach to Stop Hypertension diet alone. Fasting alters the gut microbiome, impacting bacterial taxa and gene modules associated with short-chain fatty acid production. Cross-system analyses reveal a positive correlation of circulating mucosa-associated invariant T cells, non-classical monocytes and CD4+ effector T cells with systolic blood pressure. Furthermore, regulatory T cells positively correlate with body-mass index and weight. Machine learning analysis of baseline immunome or microbiome data predicts sustained systolic blood pressure response within the fasting group, identifying CD8+ effector T cells, Th17 cells and regulatory T cells or Desulfovibrionaceae, Hydrogenoanaerobacterium, Akkermansia, and Ruminococcaceae as important contributors to the model. Here we report that the high-resolution multi-omics data highlight fasting as a promising non-pharmacological intervention for the treatment of high blood pressure in metabolic syndrome patients.

2 April 2021 in Circulation Research
Verified
Journal Article
Closed access
PDF file
EAEllen G. Avery
Ellen G. Avery
HBHendrik Bartolomaeus
Hendrik Bartolomaeus
AMAndras Maifeld
Andras Maifeld
LMLajos Marko
Lajos Marko
HWHelge Wiig
Helge Wiig
DMDominik Muller
Dominik Muller
The pathogenesis of hypertension is known to involve a diverse range of contributing factors including genetic, environmental, hormonal, hemodynamic and inflammatory forces, to name a few. There is mounting evidence to suggest that the gut microbiome plays an important role in the development and pathogenesis of hypertension. The gastrointestinal tract, which houses the largest compartment of immune cells in the body, represents the intersection of the environment and the host. Accordingly, lifestyle factors shape and are modulated by the microbiome, modifying the risk for hypertensive disease. One well-studied example is the consumption of dietary fibers, which leads to the production of short-chain fatty acids and can contribute to the expansion of anti-inflammatory immune cells, consequently protecting against the progression of hypertension. Dietary interventions such as fasting have also been shown to impact hypertension via the microbiome. Studying the microbiome in hypertensive disease presents a variety of unique challenges to the use of traditional model systems. Integrating microbiome considerations into preclinical research is crucial, and novel strategies to account for reciprocal host-microbiome interactions, such as the wildling mouse model, may provide new opportunities for translation. The intricacies of the role of the microbiome in hypertensive disease is a matter of ongoing research, and there are several technical considerations which should be accounted for moving forward. In this review we provide insights into the host-microbiome interaction and summarize the evidence of its importance in the regulation of blood pressure. Additionally, we provide recommendations for ongoing and future research, such that important insights from the microbiome field at large can be readily integrated in the context of hypertension.

25 June 2019 in Nature Reviews Nephrology
Verified
Journal Article
Closed access
PDF file
NWNicola Wilck
Nicola Wilck
ABAndrás Balogh
András Balogh
LMLajos Markó
Lajos Markó
HBHendrik Bartolomaeus
Hendrik Bartolomaeus
DMDominik Muller
Dominik Muller